Results
|
1.
|
|
|
2.
|
|
|
3.
|
|
|
4.
|
|
|
5.
|
Improvements in patient-reported outcomes in patients with psoriasis receiving etanercept plus topical therapies: results from REFINE. [electronic resource] by
- Papp, K A
- Barber, K
- Bissonnette, R
- Bourcier, M
- Lynde, C W
- Poulin, Y
- Shelton, J
- Garces, K
- Toole, J
- Poulin-Costello, M
Producer: 20160421
In:
Journal of the European Academy of Dermatology and Venereology : JEADV vol. 29
Availability: No items available.
|
|
6.
|
A Randomized, blinded assessor study to Evaluate the efFIcacy and safety of etanercept 50 mg once weekly plus as Needed topical agent vs. Etanercept 50 mg twice weekly in patients with moderate to severe plaque psoriasis (REFINE). [electronic resource] by
- Papp, K A
- Barber, K
- Bissonnette, R
- Bourcier, M
- Lynde, C W
- Poulin, Y
- Shelton, J
- Toole, J
- Vieira, A
- Poulin-Costello, M
Producer: 20151013
In:
Journal of the European Academy of Dermatology and Venereology : JEADV vol. 29
Availability: No items available.
|
|
7.
|
Sorafenib in advanced melanoma: a Phase II randomised discontinuation trial analysis. [electronic resource] by
- Eisen, T
- Ahmad, T
- Flaherty, K T
- Gore, M
- Kaye, S
- Marais, R
- Gibbens, I
- Hackett, S
- James, M
- Schuchter, L M
- Nathanson, K L
- Xia, C
- Simantov, R
- Schwartz, B
- Poulin-Costello, M
- O'Dwyer, P J
- Ratain, M J
Producer: 20061004
In:
British journal of cancer vol. 95
Availability: No items available.
|